Eli Lilly (LLY) Return on Capital Employed (2010 - 2026)

Eli Lilly (LLY) has reported Return on Capital Employed for 18 consecutive years, with 42.94% the latest figure, recorded in Q1 2026.

• Return on Capital Employed for Q1 2026 came in at 42.94%, up 806.0% year-over-year; the trailing twelve-month figure through Mar 2026 was 42.94% (up 806.0% YoY), and the FY2025 annual result was 48.39%, up 1075.0% from the prior year.
• Return on Capital Employed was 42.94% for Q1 2026 at Eli Lilly, up from 37.22% in the prior quarter.
• Over five years, Return on Capital Employed peaked at 42.94% in Q1 2026 and troughed at 20.0% in Q1 2023.
• Average Return on Capital Employed over 5 years is 30.19%, with a median of 28.23% recorded in 2024.
• Year-over-year, Return on Capital Employed tumbled 575 bps in 2023 and surged 1002 bps in 2025.
• Over 5 years, Return on Capital Employed stood at 25.64% in 2022, then grew by 19 bps to 30.47% in 2023, then rose by 9 bps to 33.16% in 2024, then grew by 12 bps to 37.22% in 2025, then rose by 15 bps to 42.94% in 2026.
• Per Business Quant data, the three most recent Return on Capital Employed figures were 42.94% in Q1 2026, 37.22% in Q4 2025, and 37.83% in Q3 2025.